Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Aguirre

Physician Assistant Bentonville, AR Physician Assistant

NPI 1336473552 CMS profile 10785636

901 Se Plaza Ave Ste 5, Bentonville, AR 72712

Open in the dashboard

General payments

$6,616

377 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Aguirre of Bentonville, AR is reported in the CMS Open Payments database as having received $6,616 across 377 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,403 79
2024 General $1,570 92
2023 General $1,219 64
2022 General $1,393 78
2021 General $1,032 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Aguirre
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brittany Aguirre were reported at $1,403. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brittany Aguirre Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,032 $132 $37–$438 $132
2022 $1,393 $155 $48–$522 $149
2023 $1,219 $167 $52–$557 $160
2024 $1,570 $178 $55–$600 $164
2025 $1,403 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,345 78 payments
  2. AbbVie, Inc. $1,198 79 payments
  3. Lilly USA, LLC $845 42 payments
  4. Novartis Pharmaceuticals Corporation $733 44 payments
  5. Genzyme Corporation $465 20 payments
  6. E.R. Squibb & Sons, L.L.C. $282 16 payments
  7. Sun Pharmaceutical Industries Inc. $271 14 payments
  8. UCB, Inc. $233 13 payments
  9. LEO Pharma Inc. $201 10 payments
  10. Pfizer Inc. $156 10 payments
  11. Other $887 51 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,326 371 payments
  2. Education $290 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,357 79 payments
  2. TALTZ $831 41 payments
  3. SKYRIZI $801 53 payments
  4. DUPIXENT $644 26 payments
  5. OLUMIANT $374 18 payments
  6. COSENTYX Dermatology $328 18 payments
  7. COSENTYX Immunology $296 20 payments
  8. SOTYKTU $282 16 payments
  9. ADBRY $180 9 payments
  10. EBGLYSS $173 9 payments
  11. Other $2,349 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

458

Median for Physician Assistant: 241

Drug cost

$365,678

Median for Physician Assistant: $4,110

Branded share of claims

31.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 17 $149,193
Dupixent Pen Dupilumab Brand 29 $111,740
Otezla Apremilast Brand 20 $94,718
Doxycycline Hyclate Generic 35 $2,835
Clobetasol Propionate Generic 43 $1,882
Ketoconazole Generic 69 $1,379
Fluorouracil Generic 15 $1,138
Hydrocortisone Generic 48 $562
Betamethasone Dipropionate Generic 14 $539
Metronidazole Generic 13 $491

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$67,112

Of which drugs: $7,890

Medicare patients

616

Average age 74

Services billed

1,818

393 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 47%
Ischemic heart disease 30%
Depression 21%
Diabetes 17%
Chronic kidney disease 17%
Osteoporosis 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 17 27 $7,887

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $302
$302 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $223
$223 — —
SKYRIZI
  • AbbVie, Inc. $164
$164 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $107
$107 — —
TALTZ
  • Lilly USA, LLC $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

377 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record